@ARTICLE{10.3389/ti.2023.10816, AUTHOR={Masset, Christophe and Kerleau, Clarisse and Blancho, Gilles and Hourmant, Maryvonne and Walencik, Alexandre and Ville, Simon and Kervella, Delphine and Cantarovich, Diego and Houzet, Aurélie and Giral, Magali and Garandeau, Claire and Dantal, Jacques and , the Nantes DIVAT Consortium and Blancho, Gilles and Branchereau, Julien and Cantarovich, Diego and Cesbron, Anne and Chapelet, Agnès and Dantal, Jacques and Delbos, Florent and Deltombe, Clément and Devis, Anne and Figueres, Lucile and Gaisne, Raphael and Garandeau, Claire and Giral, Magali and Gourraud-Vercel, Caroline and Hourmant, Maryvonne and Kandel-Aznar, Christine and Karam, Georges and Kerleau, Clarisse and Kervella, Delphine and Leclech, Alice and Leman, Claire and Masset, Christophe and Meurette, Aurélie and Renaudin, Karine and Ville, Simon and Walencik, Alexandre}, TITLE={Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients}, JOURNAL={Transplant International}, VOLUME={36}, YEAR={2023}, URL={https://www.frontierspartnerships.org/articles/10.3389/ti.2023.10816}, DOI={10.3389/ti.2023.10816}, ISSN={1432-2277}, ABSTRACT={The choice between Basiliximab (BSX) or Anti-Thymocyte Globulin (ATG) as induction therapy in non-immunized kidney transplant recipients remains uncertain. Whilst ATG may allow steroid withdrawal and a decrease in tacrolimus, it also increases infectious complications. We investigated outcomes in non-immunized patients receiving a very low dosage of ATG versus BSX as induction. Study outcomes were patient/graft survival, cumulative probabilities of biopsy proven acute rejection (BPAR), infectious episode including CMV and post-transplant diabetes (PTD). Cox, logistic or linear statistical models were used depending on the studied outcome and models were weighted on propensity scores. 100 patients received ATG (mean total dose of 2.0 mg/kg) and 83 received BSX. Maintenance therapy was comparable. Patient and graft survival did not differ between groups, nor did infectious complications. There was a trend for a higher occurrence of a first BPAR in the BSX group (HR at 1.92; 95%CI: [0.77; 4.78]; p = 0.15) with a significantly higher BPAR episodes (17% vs 7.3%, p = 0.01). PTD occurrence was significantly higher in the BSX group (HR at 2.44; 95%CI: [1.09; 5.46]; p = 0.03). Induction with a very low dose of ATG in non-immunized recipients was safe and associated with a lower rate of BPAR and PTD without increasing infectious complications.} }